This article on Epainassist.com has been reviewed by a medical professional, as well as checked for facts, to assure the readers the best possible accuracy.

We follow a strict editorial policy and we have a zero-tolerance policy regarding any level of plagiarism. Our articles are resourced from reputable online pages. This article may contains scientific references. The numbers in the parentheses (1, 2, 3) are clickable links to peer-reviewed scientific papers.

The feedback link “Was this Article Helpful” on this page can be used to report content that is not accurate, up-to-date or questionable in any manner.

This article does not provide medical advice.


Cefepime-Resistant Enterobacteriaceae : A Growing Threat to Global Healthcare

Antibiotics have been a cornerstone of modern medicine, saving millions of lives from bacterial infections. However, the emergence of antibiotic resistance is posing a significant threat to global healthcare. Among the growing list of antibiotic-resistant pathogens, Cefepime-Resistant Enterobacteriaceae (CRE) is causing particular concern in the medical community. CRE are a group of bacteria that belong to the Enterobacteriaceae family, which includes Escherichia coli, Klebsiella pneumoniae, and Enterobacter species. These bacteria have developed the ability to resist cefepime, an essential antibiotic used to treat a wide range of infections. In this article, we will delve into the challenges posed by Cefepime-Resistant Enterobacteriaceae and explore potential strategies for tackling this emerging threat.

Understanding Cefepime-Resistant Enterobacteriaceae and its Mechanisms of Resistance:

Cefepime-Resistant Enterobacteriaceae are Gram-negative bacteria that possess a crucial enzyme called Extended-Spectrum β-Lactamases (ESBLs) or AmpC β-lactamases. These enzymes effectively break down cefepime and other β-lactam antibiotics, rendering them ineffective in combating infections. Additionally, CRE can also acquire resistance genes through mobile genetic elements like plasmids, enabling the rapid spread of resistance among bacterial populations. The ability of CRE to develop resistance through multiple mechanisms makes them particularly challenging to treat, as they become insensitive to a broad range of antibiotics.

The Global Impact of Cefepime-Resistant Enterobacteriaceae:

The rise of Cefepime-Resistant Enterobacteriaceae has been observed worldwide, affecting both healthcare settings and the community. In hospitals, CRE infections can lead to severe healthcare-associated infections, including urinary tract infections, bloodstream infections, and pneumonia. Due to their ability to spread easily and persist in healthcare environments, CRE outbreaks can be challenging to contain, posing a significant risk to vulnerable patients. Moreover, the community-acquired CRE infections are also on the rise, leading to increased morbidity and mortality among individuals with compromised immune systems or underlying health conditions.

Challenges in Diagnosis and Treatment of Cefepime-Resistant Enterobacteriaceae infections:

Detecting Cefepime-Resistant Enterobacteriaceae infections presents challenges for healthcare providers. Standard laboratory methods may not always identify CRE accurately, leading to delayed diagnosis and appropriate treatment. CRE infections have been associated with high mortality rates due to limited treatment options. Carbapenems, another class of antibiotics, have been considered the last line of defense against CRE. However, carbapenem-resistant CRE strains have emerged, further limiting therapeutic choices. As a result, managing CRE infections requires a multidisciplinary approach, including infection control measures, antibiotic stewardship, and the development of novel treatment strategies.

Antibiotic Stewardship and Preventive Measures:

To combat the emergence and spread of Cefepime-Resistant Enterobacteriaceae, antibiotic stewardship is crucial. Healthcare facilities must prioritize the appropriate use of antibiotics, ensuring that these life-saving drugs are prescribed only when necessary. Implementing infection prevention and control measures, such as hand hygiene, proper disinfection practices, and patient isolation, can help curb the transmission of CRE in healthcare settings. In the community, raising awareness about antibiotic resistance and encouraging responsible antibiotic use among patients and healthcare providers is essential in slowing the progression of Cefepime-Resistant Enterobacteriaceae  or CRE.

Research and Development of Novel Treatments for Cefepime-Resistant Enterobacteriaceae infections:

Addressing the challenges posed by CRE requires a continuous focus on research and development of new treatment options. Scientists are exploring alternative therapies, such as combination antibiotic regimens and bacteriophage therapy, as potential solutions to combat Cefepime-Resistant Enterobacteriaceae infections. Additionally, the development of new antibiotics with unique mechanisms of action is critical in overcoming CRE’s resistance mechanisms.


The emergence of Cefepime-Resistant Enterobacteriaceae represents a critical challenge in antibiotic treatment and infection control. CRE’s ability to evade multiple antibiotics demands a proactive and comprehensive response from the medical community. Through antibiotic stewardship, preventive measures, and research efforts, we can strive to limit the impact of Cefepime-Resistant Enterobacteriaceae and preserve the effectiveness of our existing antibiotic arsenal. Only by collaborating globally can we tackle the growing threat of Cefepime-Resistant Enterobacteriaceae and protect the future of healthcare.


  1. World Health Organization. (2021). Antibiotic resistance. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
  2. Public Health England. (2021). English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report. https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report
  3. Centers for Disease Control and Prevention. (2021). Antibiotic Resistance Threats in the United States, 2021. https://www.cdc.gov/drugresistance/pdf/threats-report/2021-ar-threats-report-508.pdf
  4. Gupta, N., Limbago, B. M., Patel, J. B., & Kallen, A. J. (2011). Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clinical Infectious Diseases, 53(1), 60-67. doi:10.1093/cid/cir202
  5. Tängdén, T., Giske, C. G., & Global Carbapenemase-Producing Enterobacteriaceae Working Group. (2015). Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment, and infection control. Journal of Internal Medicine, 277(5), 501-512. doi:10.1111/joim.12348
  6. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., & WHO Pathogens Priority List Working Group. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases, 18(3), 318-327. doi:10.1016/S1473-3099(17)30753-3

Also Read:

Team PainAssist
Team PainAssist
Written, Edited or Reviewed By: Team PainAssist, Pain Assist Inc. This article does not provide medical advice. See disclaimer
Last Modified On:July 25, 2023

Recent Posts

Related Posts